Harbor Advisors LLC Makes New $241,000 Investment in Novo Nordisk A/S (NYSE:NVO)

Harbor Advisors LLC bought a new position in Novo Nordisk A/S (NYSE:NVO) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 2,800 shares of the company’s stock, valued at approximately $241,000.

Several other large investors have also recently added to or reduced their stakes in NVO. Raymond James Financial Inc. acquired a new stake in Novo Nordisk A/S in the fourth quarter worth $404,910,000. Sustainable Growth Advisers LP increased its position in Novo Nordisk A/S by 23.6% in the fourth quarter. Sustainable Growth Advisers LP now owns 5,340,803 shares of the company’s stock worth $459,416,000 after buying an additional 1,021,498 shares during the period. Amundi increased its position in Novo Nordisk A/S by 26.4% in the fourth quarter. Amundi now owns 3,311,456 shares of the company’s stock worth $283,615,000 after buying an additional 692,567 shares during the period. Parnassus Investments LLC acquired a new position in shares of Novo Nordisk A/S during the fourth quarter valued at $51,072,000. Finally, DAVENPORT & Co LLC increased its holdings in shares of Novo Nordisk A/S by 75.1% during the fourth quarter. DAVENPORT & Co LLC now owns 1,052,712 shares of the company’s stock valued at $90,477,000 after purchasing an additional 451,641 shares during the period. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Trading Down 2.4 %

Shares of NVO stock opened at $76.88 on Friday. The stock has a 50-day simple moving average of $83.34 and a 200 day simple moving average of $100.98. Novo Nordisk A/S has a fifty-two week low of $73.80 and a fifty-two week high of $148.15. The stock has a market capitalization of $344.98 billion, a P/E ratio of 23.37, a P/E/G ratio of 0.90 and a beta of 0.42. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, sell-side analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be given a $0.7874 dividend. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. This represents a dividend yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio (DPR) is 47.72%.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Kepler Capital Markets raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Thursday, March 13th. Finally, BMO Capital Markets lowered their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Novo Nordisk A/S has a consensus rating of “Moderate Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.